LONDON, June 9 (Reuters) - AstraZeneca said onThursday it had agreed to sell the commercialisation rights forits portfolio of anaesthetics outside the United States to SouthAfrica's Aspen Pharmacare for an initial payment of$520 million.
The agreement covers seven established medicines - Diprivan for general anaesthesia, EMLA, a topical anaesthetic, and fivelocal anaesthetics - the British company said.
Aspen will also pay AstraZeneca up to $250 million inproduct sales-related payments as well as double-digitpercentage trademark royalties. (Reporting by Paul Sandle; Editing by Ben Hirschler)